NewAmsterdam Pharma Company NAMS Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's other operating expenses?
- NewAmsterdam Pharma Company (NAMS) reported other operating expenses of $61.46M in Q1 2026.
- How has NewAmsterdam Pharma Company's other operating expenses changed year-over-year?
- NewAmsterdam Pharma Company's other operating expenses decreased by 14.5% year-over-year, from $71.9M to $61.46M.
- What is the long-term trend for NewAmsterdam Pharma Company's other operating expenses?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's other operating expenses has grown at a 63.2% compound annual growth rate (CAGR), from $34.98M to $248.19M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.